Clinical Rheumatology

, Volume 24, Issue 3, pp 278–284 | Cite as

Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis

Original Article

Abstract

The cartilage oligometrix matrix protein (COMP) is a noncollagenous protein, a glycoprotein, the function of which is to bind to type II collagen fibres and stabilise the collagen fibre network in the articular cartilage. In the serum of the normal population the COMP level is 5 μg/ml. An increased level of COMP in the synovial fluid was described in the early stage of rheumatoid arthritis (RA), whereas in advanced stages of RA, the level of COMP decreased. In this study we assessed the serum COMP level in patients with RA and knee osteoarthritis (OA) and found a correlation between the serum COMP level and other markers as well as bone mass density (BMD) changes, activity of disease, disease duration and the age of the patients. The blood was collected from 30 RA patients and 30 OA patients who constituted the control group. The serum COMP level was determined using an inhibition enzyme-linked immunosorbent assay (ELISA). The average value of the serum COMP level in RA patients was 10.4±3.6 U/l. There was a correlation between the serum COMP level and the age of RA patients (p<0.005) and disease activity score (DAS) value (p<0.01). According to correlation coefficients, the serum COMP level was independent of stage of disease, number of painful and swollen joints, duration of morning stiffness, disease duration and titre of the Waaler–Rose test. The influence of rheumatoid nodule presence on the serum COMP level was shown (p<0.05). In RA patients with erythrocyte sedimentation rate (ESR) values below 20 mm/h compared with patients with ESR values over 60 mm/h, the serum COMP level was observed to be significantly lower (p<0.05). The average value of COMP in OA patients was 10.4±2.7 U/l. No correlation was found between the serum COMP level and patients’ age and disease duration. There was a correlation between the serum COMP level and Western Ontario and McMaster Universities (WOMAC) index pain scale for the lower limbs (p<0.005) and T-score value of densitometry examinations (p<0.036) in OA patients. No statistical differences were found between the average serum COMP level in RA and OA patients.

Keywords

Cartilage Knee osteoarthritis Rheumatoid arthritis Serum cartilage oligomeric matrix protein (COMP) 

References

  1. 1.
    Saxne T, Heinegard D (1992) Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 31:583–591PubMedGoogle Scholar
  2. 2.
    Morgelin M, Heinegard D, Engel J, Paulsson M (1992) Electron microscopy of native cartilage oligomeric matrix protein purified from the Swarm rat chondrosarcoma reveals a five-armed structure. J Biol Chem 267:6137–6141PubMedGoogle Scholar
  3. 3.
    Hedbom E, Antonsson P, Hjerpe A, Aeschlimann D, Paulsson M, Rosa-Pimentel E, Sommarin Y, Wendel M, Oldberg A, Heinegard D (1992) Cartilage matrix proteins: an acidic oligomeric protein (COMP) detected only in cartilage. J Biol Chem 267:6132–6136PubMedGoogle Scholar
  4. 4.
    Franzen A, Heinegard D, Solursh M (1997) Evidence for sequential appearance of cartilage matrix proteins in developing mouse limbs and in cultures of mouse mesenchymal cells. Differentiation 36:199–210Google Scholar
  5. 5.
    DiCesare P, Morgelin M, Mann K, Paulsson M (1994) Cartilage oligomeric matrix protein and thrombospondin. Purification from articular cartilage, electron microscopic structure, and chondrocyte binding. Eur J Biochem 223:927–937PubMedGoogle Scholar
  6. 6.
    Wollheim FA, Eberhardt KB, Johnson U, Saxne T (1997) HLA DRB1* typing and cartilage oligomeric matrix protein (COMP) as predictors of joint destruction in recent-onset rheumatoid arthritis. Br J Rheumatol 36:847–849CrossRefPubMedGoogle Scholar
  7. 7.
    Mansson B, Carey D, Alini M, Ionescu M, Rosenberg LC, Poole AR, Heinegard D, Saxne T (1995) Cartilage and metabolism in rheumatoid arthritis. J Clin Invest 95:1071–1077PubMedGoogle Scholar
  8. 8.
    Forslind K, Eberhardt K, Jonsson A, Saxne T (1992) Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis. Br J Rheumatol 31:593–598PubMedGoogle Scholar
  9. 9.
    Lindquist EK, Saxne T, Eberhard K (2002) Relationship between functional capacity, disease activity, pain and joint destruction during the first 10 years of rheumatoid arthritis. Ann Rheum Dis 61 [Suppl 1]:74Google Scholar
  10. 10.
    Fex E, Eberhardt K, Saxne T (1997) Tissue-derived macromolecules and markers of inflammation in serum in early rheumatoid arthritis: relationship to development of joint destruction in hands and feet. Br J Rheumatol 36:1161–1165CrossRefPubMedGoogle Scholar
  11. 11.
    Peterson IF, Boegard T, Dahlstrom J, Svensson B, Heinegard D, Saxne T (1996) Bone scan and serum markers of bone and cartilage in patients with knee pain and osteoarthritis. Osteoarthritis Cartilage 6:33–39CrossRefGoogle Scholar
  12. 12.
    Vilim V, Olejarova M, Machacek S, Gatterova J, Kraus VB, Pavelka K (2002) Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis. Osteoarthritis Cartilage 10:707–713CrossRefPubMedGoogle Scholar
  13. 13.
    Haberhauer GF, Feyertag J, Kittl EM, Bauer K, Dunky A (2002) Steroid treatment normalises the variability and levels of serum COMP in RA patients, indicating a possibility to monitor effect of cartilage protective drugs. Rheum Dis 61 [Suppl 1]:200Google Scholar
  14. 14.
    Haberhauer GF, Feyertag J, Kitti EM, Bauer K, Dunky A (2003) Rapid decrease of COMP serum levels in patients with active RA undergoing IV steroid treatment. Ann Rheum Dis 62 [Suppl 1]:166Google Scholar
  15. 15.
    Crnkic M, Masson B, Larsson L, Geborek P, Heinegard D, Saxne T (2003) Serum cartilage oligomeric matrix protein (COMP) decreased in rheumatoid arthritis patients treated with infliximab or etanercept. Arthritis Res Ther 5:R181–R185CrossRefPubMedGoogle Scholar
  16. 16.
    Den Broeder AA, Jonsten LAB, Saxne T, Heinegard D, Fenner H, Miltenburg AMM, Frasa WLH, van Tils LJ, Burman WA, van Riel PLCM, van de Putte LBA, Barrera P (2002) Long term anti-tumor necrosis factor alfa monotherapy in rheumatoid arthritis: effect on radiological course and endothelial activation. Ann Rheum Dis 61:311–318CrossRefPubMedGoogle Scholar
  17. 17.
    Neidhart M, Hauser N, Paulsson M et al (1997) Small fragments of cartilage oligomeric matrix protein in synovial fluid and serum as markers for cartilage degradation. Br J Rheumatol 36:1151–1160CrossRefPubMedGoogle Scholar
  18. 18.
    Dahlberg L, Roos H, Saxne T et al (1994) Cartilage metabolism in the uninjured knee of the same patient. Ann Rheum Dis 53:823–827PubMedGoogle Scholar
  19. 19.
    Saxne T, Heinegard D (1992) Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood (published erratum appears in Br J Rheumatol 32:247). Br J Rheumatol 31:583–591PubMedGoogle Scholar
  20. 20.
    Arnett FC (1989) Revised criteria for the classification of rheumatoid arthritis. Bul Rheum Dis 38:1–6Google Scholar
  21. 21.
    Steinbrocker O, Treger H, Cornelius H (1949) Therapeutic criteria in rheumatoid arthritis. JAMA 140:659–662Google Scholar
  22. 22.
    van der Heijde DMFM, van ’t Hof MA, van Riel PLCM, van de Putte LBA (1993) Development of a disease activity score based on judgement in clinical practice by rheumatologists. J Rheumatol 20:579–581PubMedGoogle Scholar
  23. 23.
    Altman R (1991) Classification of disease: osteoarthritis. Semin Arthritis Rheum 21 [Suppl 2]:40–47CrossRefGoogle Scholar
  24. 24.
    Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LWJ (1988) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833–1840PubMedGoogle Scholar
  25. 25.
    Kellgren JH, Lawrence SJ (1957) Radiological assessment of osteo-arthrosis. Ann Rheum Dis 16:494–502PubMedGoogle Scholar
  26. 26.
    Robert R, Sokal F, Rohlf J (1986) Biometry. Freeman, New York, pp 354–359, 691–714Google Scholar
  27. 27.
    Marti C, Neidhart M, Gerber T et al (1999) Cartilage oligomeric matrix protein (COMP). Die Rolle eines nichtkollagenem Knorpel-Matrix-Proteins als Marker der Krankheitsaktivität und Gelenkzerstörung bei Patienten mit rheumatoider Arthritis und Arthrose. Z Rheumatol 58:78–87CrossRefGoogle Scholar
  28. 28.
    Feyertag J, Haberhauer GF, Kittl EM et al (2002) Changes in clinical scorings are correlated to changes in cartilage oligomeric matrix protein (COMP) levels, but not to systemic inflammation markers in patients with rheumatoid arthritis (RA). Ann Rheum Dis 61 [Suppl 1]:75Google Scholar

Copyright information

© Clinical Rheumatology 2004

Authors and Affiliations

  1. 1.Department of RheumatologyCentral Clinical HospitalWarsawPoland

Personalised recommendations